Breaking News

Canada Continues Recommending AstraZeneca's COVID-19 Vaccine

March 19, 2021 • 6:59 am CDT
(Precision Vaccinations)

Toronto-based Thrombosis Canada announced it reviewed recent reports from the United Kingdom and Europe relating to the COVID-19 vaccine made by AstraZeneca and developing a very rare type of thrombosis (blood clots) that is associated with thrombocytopenia (low blood platelets).

It is the view of Thrombosis Canada as of March 18, 2021, that, based on all available evidence, people who receive the AstraZeneca vaccine are not at increased risk of developing blood clots when compared with the general population.

However, the AstraZeneca vaccine may be associated with extremely rare cases of blood clots that occur in the brain (called cerebral sinus vein thrombosis) and are associated with low blood platelets.

These blood clots were found to occur in 1 in 250,000 to 1 in 500,000 people who received the vaccine.

By comparison, people who have COVID-19 are at much higher risk of developing blood clots, which occur in about 1 in 20 people in hospital with COVID-19 and about 1 in 100 people who have COVID-19 but are not in a hospital.

“Thrombosis Canada strongly recommends that people receive vaccinations for COVID-19, including the vaccine made by AstraZeneca,” stated Thrombosis Canada President Jim Douketis in a press release.

"That’s what we are telling the many patients who have been asking us because of the reports from Europe. The benefits of preventing blood clots and other diseases caused by COVID-19 far outweigh any possible risks, which we consider very low.”

Thrombosis Canada further strongly recommends that the following groups of people receive vaccinations for COVID-19:

1) people who have had a previous blood clot
2) people with a family member who has developed a blood clot
3) people with a hereditary clotting tendency (e.g., factor V Leiden mutation)
4) people who are receiving blood thinner medications

Thrombosis Canada is dedicated to education and awareness of the thrombotic disease.

On February 26, 2021, Health Canada authorized two vaccines, the COVID-19 vaccine manufactured by AstraZeneca and developed in partnership with Oxford University and the Serum Institute of India’s version of the AstraZeneca vaccine, known as CoviShield.

Medical Review by